β-Amyloid Amorphous Aggregates Induced by the Small Natural Molecule Ferulic Acid

Bramanti, Emilia; Fulgentini, Lorenzo; Bizzarri, Ranieri; Lenci, Francesco; Sgarbossa, Antonella

doi:10.1021/jp4079986

Cited by 35 publications

(30 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The excitation and the emission monochromators were set at 405 nm and light diffusion was measured at 90 . 29,30 Indeed, since the light scattering intensity is proportional to the size of all of the species in solution, Rayleigh scattering is a suitable tool to study the time evolution of protein assemblies. Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Assuming a Poisson distribution, we may estimate that in 20 mL uctuations should arise from a particle concentration as low as x10 À17 M. Therefore, we can safely assume that monomers and small oligomers are the largely predominant species in our systems. 30 2.3.2 Thioavin T spectrouorometric measurements. Thioavin T (ThT) uorescence emission was monitored using a FLUOROMAX 4 HORIBA-Jobin Yvon spectrouorimeter.…”

Section: Sample Preparation: Ab and Compoundsmentioning

confidence: 99%

See 1 more Smart Citation

Curcumin-like compounds designed to modify amyloid beta peptide aggregation patterns

et al. 2017

Self Cite

View full text Add to dashboard Cite

Curcumin is a natural polyphenol able to bind the amyloid beta peptide, which is related to Alzheimer’s\ud disease, and modify its self-assembly pathway. This paper focuses on a multi-disciplinary study that starts\ud from the design of curcumin-like compounds with the key chemical features required for inhibiting\ud amyloid beta aggregation, and reports the effects of these compounds on the in vitro aggregation of\ud amyloid beta peptides. Chemoinformatic screening was performed through the calculation of molecular\ud descriptors that were able to highlight the drug-like profile, followed by docking studies with an amyloid\ud beta peptide fibril. The computational design underlined two different scaffolds that were easily\ud synthesized in good yields. In vitro experiments, ranging from fluorescence spectroscopy and confocal\ud microscopy up to small angle X-ray scattering, provided evidence that the synthesized compounds are\ud able to modify the aggregation pattern of amyloid beta peptides both in the secondary structures, and in\ud terms of the overall structure dimensions. The cytotoxic potential of the synthesized compounds was\ud finally tested in vitro with a model neuronal cell line (LAN5). The overall view of this study suggests new\ud concepts and potential difficulties in the design of novel drugs against diverse amyloidoses, including\ud Alzheimer’s disease

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Sample Preparation: Ab and Compoundsmentioning

confidence: 99%

Curcumin-like compounds designed to modify amyloid beta peptide aggregation patterns

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…The small natural molecule ferulic acid can inhibit Aβ in vitro in the early stages of Aβ-fibrillogenesis [76]. FA can improve hyperactivity, object recognition, and spatial, working, and reference memories through decreasing Aβ production and reducing amyloidogenic APP proteolysis [77].…”

Section: Figure 1 Dss-mediated Resolution Of Aβ In Alzheimer's Diseasementioning

confidence: 99%

Danggui-Shaoyao-San: New Hope for Alzheimer's Disease

Fu¹,

Wang²,

Wang³

et al. 2016

Aging and disease

View full text Add to dashboard Cite

Danggui-Shaoyao-San (DSS), also called Toki-shakuyaku-san (TJ-23) or Dangguijakyaksan (DJS), is a well-known herbal formula (Angelica sinensis (Oliv.) Diels., Ligusticum chuanxiong Hort., Paeonia lactiflora pall., Poria cocos (Schw.) Wolf, Alisma orientalis (Sam.) Juzep., Atractylodes macrocephala Koidz.), which has been widely used in oriental countries for the treatment of various gynecological diseases. Recent studies show that DSS has an effect on free radical-mediated neurological diseases and exhibits anti-inflammatory and antioxidant activities and reduces cell apoptosis in the hippocampus. In addition, DSS mediates the modulation of central monoamine neurotransmitter systems and ameliorates dysfunction of the central cholinergic nervous system and scopolamine-induced decrease in ACh levels. DSS improves the function of the dopaminergic, adrenergic, and serotonergic nervous systems. Interestingly, DSS can alleviate cognitive dysfunction of Alzheimer's disease (AD) patients, suggesting that it is a useful therapeutic agent for AD. This paper reviews the mechanism of DSS for the treatment of AD.

show abstract

“…Ferulic acid had disruptive effects on A␤ fibrils [246][247][248]. It inhibited the transition of A␤ 42 monomers to oligomers, but accelerated the transition from oligomers to fibrils [249].…”

Section: Natural Productsmentioning

confidence: 99%

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

Froestl

Pfeifer

Muhs

2014

JAD

View full text Add to dashboard Cite

Scientists working in the field of Alzheimer's disease and, in particular, cognitive enhancers, are very productive. The review "Drugs interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs" was accepted in October 2012. In the last 20 months, new targets for the potential treatment of Alzheimer's disease were identified. Enormous progress was realized in the pharmacological characterization of natural products with cognitive enhancing properties. This review covers the evolution of research in this field through May 2014.

show abstract

β-Amyloid Amorphous Aggregates Induced by the Small Natural Molecule Ferulic Acid

Cited by 35 publications

References 42 publications

Curcumin-like compounds designed to modify amyloid beta peptide aggregation patterns

Curcumin-like compounds designed to modify amyloid beta peptide aggregation patterns

Danggui-Shaoyao-San: New Hope for Alzheimer's Disease

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

Contact Info

Product

Resources

About